Table 3.
Monoamine or metabolite | Model 1 | Model 2 | ||||||
---|---|---|---|---|---|---|---|---|
Vehicle – Vehicle | Vehicle – LNFPIII | PB/PM – Vehicle | PB/PM – LNFPIII | Vehicle – Vehicle | Vehicle – LNFPIII | PB/DEET/CORT/DFP – Vehicle | PB/DEET/CORT/DFP-LNFPIII | |
5-HT | 80.29 ± 7.02 | 94.69 ± 4.46 b | 96.99 ± 6.78 b | 81.30 ± 6.60 | 80.29 ± 9.30 | 69.29 ± 5.78 | 107.44 ± 9.30 a | 100.87 ± 14.27 a |
5-HIAA | 0.66 ± 0.04 | 0.71 ± 0.13 | 0.74 ± 0.09 | 0.66 ± 0.06 | 0.66 ± 0.12 | 0.71 ± 0.09 | 1.02 ± 0.22 a | 1.42 ± 0.25 a |
NE | 66.83 ± 8.12 | 70.10 ± 12.17 | 59.16 ± 5.43 | 62.21 ± 8.90 | 95.83 ± 6.65 | 93.08 ± 9.90 | 90.84 ± 3.67 | 110.32 ± 11.65 |
MHPG | 43.21 ± 1.98 | 48.77 ± 3.10 | 41.90 ± 1.80 | 47.55 ± 5.96 | 34.96 ± 2.58 | 39.45 ± 4.81 | 43.15 ± 3.79 a | 51.82 ± 3.24a |
Data are presented as mean ± SEM; unit: ng/mg protein; n=6 per group, except the PB/DEET/CORT/DFP-Vehicle group, which was n=8).
a and b indicate significant main effect for PB/DEET/CORT/DFP or Treatment (PB/PM x LNFPIII) interaction, respectively, after a two-way ANOVA (p ≤ 0.05) and are bolded.
Italicized values indicate trend (p < 0.10) for main effect of LNFPIII. Abbreviations: 5-HT: serotonin; 5-HIAA: 5-hydroxyindoleacetic acid; MHPG: 3-methoxy-4-hydroxyphenylglycol; NE: norepinephrine; PB: pyridostigmine bromide; PM: Permethrin; DEET: N,N-Diethyl-methylbenzamide; DFP: diisopropylfluorophosphate; CORT: corticosterone; LNFPIII: lacto-N-fucopentaose III.